Peptides & Therapeutics

A preclinical study tested butyrate-conjugated m-P14 in experimental anti-GBM nephritis and pharmacokinetic testing in dogs.

A preclinical research explainer of an oncolytic adenovirus engineered to express a peptide CDK4/6 inhibitor in colorectal cancer models.

A research explainer of a Controlled Release Society workshop report on oral peptide delivery, formulation enhancers, development programs, and the limits of translating preclinical findings to humans.

A source published on 2026-06-01 describes P5, a substrate-competitive decapeptide that inhibited Seneca Valley Virus 3C protease and preserved reported innate-immune signaling mechanisms in experimental systems.

A preclinical colon-cancer study evaluated TAMpep-IP, a peptide conjugate intended to inhibit STAT6 signaling in M2-like macrophages. Cell and mouse-model findings linked treatment with macrophage, tumor-microenvironment, and CD8-positive T-cell changes, but they do not establish human benefit or safety.

A fresh chromatography study and an independent immune-risk study show why therapeutic-peptide impurities need two different kinds of scrutiny: physical separation and biological testing.

Two platelet studies place MNK1 in different protective circuits: a fresh study uses its MYH9-binding role to block YAP1 recruitment, while independent full-text evidence maps a Dicer–microRNA feedback response during platelet activation.

Two preclinical formulation studies used quality-by-design workflows to develop sodium-caprate oral tablets for tirzepatide and semaglutide. Their differing animal exposure patterns show why enhancer amount, tablet mechanics, and peptide properties must be optimized together.

Two rat studies paired locally placed hydrogels with different therapeutic peptides after brachial plexus root avulsion. Their shared signal links movement recovery to preserving motor neurons and rebuilding the nerve-to-muscle pathway, while leaving clinical translation untested.

A new computational study designed protease-resistant peptides predicted to engage GIP, GLP-1, and glucagon receptors, while an independent phase 2a retatrutide trial shows why such candidates still require direct pharmacologic and clinical validation.

Three studies connect rapid measurements of peptide shape in solution with molecular simulations that characterize structural flexibility and rank affinity changes, outlining a more evidence-linked way to choose which peptide leads to synthesize next.

Two preclinical studies used different intranasal nanocarriers to move functional peptides toward the brain, highlighting that successful delivery requires both measurable exposure and preserved biological activity.

Two preclinical studies found that RL-QN15 and AP10W influenced several repair processes at once, linking inflammatory control with epithelial survival, cell migration, and tissue rebuilding in rodent wound models.

Two preclinical studies attacked oral peptide delivery with multiple coordinated barriers: a self-unfolding insulin foil improved rat exposure, while a lipid-and-capsule system protected exenatide in laboratory tests.

A fresh CAR T-cell study and an independent peptide-characterization study examine how short VIP-receptor antagonists can counter an immunosuppressive neuropeptide pathway in preclinical cancer models.

Two preclinical studies used enzyme-cleavable peptide chemistry to keep a pharmacophore or cytotoxic drug inactive until a biological trigger released it. Their results highlight both the promise and the selectivity problem of enzyme-gated delivery.

A fresh unified prediction platform and an earlier hemolysis classifier show how computational peptide screening is expanding from one safety property to several developability constraints.

Two 2026 mouse studies used different peptide-engineering strategies to concentrate mitochondrial protection in kidneys damaged by ischemia and reperfusion.

The SELECT trial tested whether the GLP-1 peptide semaglutide reduces heart attacks and strokes in people with obesity and established cardiovascular disease, without diabetes.

A trial of parathyroid hormone (1-34), an injectable peptide, reduced new vertebral fractures and raised bone density in postmenopausal women with osteoporosis.

A short-lived gut hormone, re-engineered to survive in the body, drove large weight reduction in a major trial — a case study in the peptide-drug strategy of stabilizing the body's own signals.

Tirzepatide, an engineered peptide that activates two gut-hormone receptors at once, produced large weight reduction in a phase 3 trial — extending the GLP-1 story.